Bloomberg Intelligence: US Factory Activity Contracts (Podcast)

US manufacturing activity contracted for the third consecutive month in May, with imports hitting a 16-year low amid rising tariffs. In corporate news, Sanofi is acquiring Blueprint Medicines for at least $9.1 billion, and Bristol-Myers Squibb will pay BioNTech up to $11.1 billion for a cancer drug license, while Moderna received FDA approval for its updated COVID vaccine; TAE Technologies also secured over $150 million in funding for fusion energy development, as Wall Street navigates economic data and geopolitical factors.

Analysis

US manufacturing activity experienced its third consecutive month of contraction in May 2025, with a notable gauge of imports declining to a 16-year low, primarily attributed to firms scaling back operations in response to higher tariffs. This challenging macroeconomic backdrop, as highlighted by Susan Spence from the Institute for Supply Management, is contributing to market uncertainty, with Wall Street investors carefully scrutinizing economic data, tariff implications, and geopolitical developments, resulting in wavering stock performance and the US dollar approaching its lowest level since 2023. Amidst this economic climate, the pharmaceutical and biotech sectors demonstrate significant activity: Sanofi has agreed to acquire Blueprint Medicines Corp. for at least $9.1 billion to expand its footprint in rare immunological diseases, while Bristol-Myers Squibb Co. will pay BioNTech SE up to $11.1 billion to license a next-generation cancer drug. Additionally, Moderna secured FDA approval for its second-generation Covid vaccine for specific adult and at-risk demographics. In the energy sector, TAE Technologies, a fusion energy company, announced it has raised over $150 million in its latest funding round, exceeding its target and signaling investor confidence in its innovative approach to clean energy. The general market sentiment is mixed with an uncertain tone, although the specific corporate developments in biotech carry positive sentiment signals for the involved companies (SNY: 0.6, BPMC: 0.9, BMY: 0.6, BNTX: 0.9, MRNA: 0.8).

Key Decisions for Investors

• Investors should closely monitor US manufacturing indicators and import data, as persistent contraction driven by tariffs could signal broader economic headwinds and increased market volatility.
• The significant M&A activity in the biotech sector, evidenced by Sanofi's $9.1 billion+ acquisition and Bristol-Myers Squibb's $11.1 billion licensing deal, suggests continued investment focus on innovation; thus, evaluating companies with strong pipelines in oncology and rare diseases may be prudent.
• Moderna's new FDA vaccine approval presents a company-specific catalyst, though its impact should be weighed against the evolving long-term demand landscape for COVID-19 vaccines.
• Given the mixed economic signals, wavering stock markets, and a weakening dollar, investors might consider a cautious and selective approach, while acknowledging the long-term growth potential in emerging technology sectors like fusion energy, as highlighted by TAE Technologies' successful funding round.